Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort

Circulation

Volumn 126, Issue 22, 2012, Pages 2556-2564

  Horsfall, Laura J ^a   Nazareth, Irwin ^a   Petersen, Irene ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antioxidants; cardiovascular diseases; epidemiology; follow up studies; risk factors

Indexed keywords

BILIRUBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ANGINA PECTORIS; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEATH; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; UNITED KINGDOM;

AGED; ANTIOXIDANTS; BILIRUBIN; COHORT STUDIES; CORONARY DISEASE; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84870251882     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.114066     Document Type: Article

References (46)

1. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR, Jansen PL. Bilirubin UDPglucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem. 1994;269:17960-17964.
2. Borucki K, Weikert C, Fisher E, Jakubiczka S, Luley C, Westphal S, Dierkes J. Haplotypes in the UGT1A1 gene and their role as genetic determinants of bilirubin concentration in healthy German volunteers. Clin Biochem. 2009;42:1635-1641.
3. McArdle PF, Whitcomb BW, Tanner K, Mitchell BD, Shuldiner AR, Parsa A. Association between bilirubin and cardiovascular disease risk factors: using mendelian randomization to assess causal inference. BMC Cardiovasc Disord. 2012;12:16.
4. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171-1175.
5. Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham Offspring Study. Am J Cardiol. 2001;87:1196-1200; A4, A7.
6. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol. 1996;51:859-862.
7. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA. 1988;85: 9748-9752.
8. Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA. 2009;106:5171-5176.
9. Stocker R, Peterhans E. Antioxidant properties of conjugated bilirubin and biliverdin: biologically relevant scavenging of hypochlorous acid. Free Radic Res Commun. 1989;6:57-66.
10. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235:1043-1046.
11. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, And Survival Analysis. New York, NY: Springer; 2001.
12. Kawamura K, Ishikawa K, Wada Y, Kimura S, Matsumoto H, Kohro T, Itabe H, Kodama T, Maruyama Y. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol. 2005;25:155-160.
13. Jansen T, Hortmann M, Oelze M, Opitz B, Steven S, Schell R, Knorr M, Karbach S, Schuhmacher S, Wenzel P, Munzel T, Daiber A. Conversion of biliverdin to bilirubin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1: evidence for direct and indirect antioxidant actions of bilirubin. J Mol Cell Cardiol. 2010;49:186-195.
14. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood). 2003;228:568-571.
15. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006;114:1476-1481.
16. Chen YH, Hung SC, Tarng DC. Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2011;6: 567-574.
17. Booth N. What are the read codes? Health Libr Rev. 1994;11:177-182.
18. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf. 2009;18:76-83.
19. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12:171-177.
20. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the general practice research database: a systematic review. Br J Gen Pract. 2010;60:e128-e136.
21. Chen SM, Li YG, Wang DM. Study on changes of heme oxygenase-1 expression in patients with coronary heart disease. Clin Cardiol. 2005; 28:197-201.
22. Dave S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf. 2009;18: 704-707.
23. Szatkowski L, Lewis S, McNeill A, Huang Y, Coleman T. Can data from primary care medical records be used to monitor national smoking prevalence? J Epidemiol Community Health. 2012;66:791-795.
24. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control. 1974;19:716-723.
25. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, Baillie TA. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002;30:505-512.
26. Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther. 2010;87:65-73.
27. Thanassoulis G, O'Donnell CJ. Mendelian randomization: nature's randomized trial in the post-genome era. JAMA. 2009;301:2386-2388.
28. Stender S, Frikke-Schmidt R, Nordestgaard BG, Grandec P, Tybjaerg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: three mendelian randomization studies and a meta-analysis [published online ahead of print July 16, 2012]. J Intern Med. doi:10.1111/j.1365-2796.2012.02576.x.
29. Lin R, Wang Y, Fu W, Zhang D, Zheng H, Yu T, Shen M, Lei R, Wu H, Sun A, Zhang R, Wang X, Xiong M, Huang W, Jin L. Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population. Pharmacogenet Genomics. 2009;19:310-318.
30. Anderson CD, Nalls MA, Biffi A, Rost NS, Greenberg SM, Singleton AB, Meschia JF, Rosand J. The effect of survival bias on case-control genetic association studies of highly lethal diseases. Circ Cardiovasc Genetics. 2011;4:188-196.
31. Williams P, Pendyala L, Superko R. Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes: an example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease. BMC Med Genet. 2011;12:42.
32. Okuhara K, Kisaka T, Ozono R, Kurisu S, Inoue I, Soga J, Yano Y, Oshima T, Kihara Y, Yoshizumi M. Change in bilirubin level following acute myocardial infarction is an index for heme oxygenase activation. South Med J. 2010;103:876-881.
33. Ehmer U, Kalthoff S, Fakundiny B, Pabst B, Freiberg N, Naumann R, Manns MP, Strassburg CP. Gilbert syndrome redefined: a complex genetic haplotype influences the regulation of glucuronidation. Hepatology. 2012;55: 1912-1921.
34. Rollinghoff W, Paumgartner G, Preisig R. Nicotinic acid test in the diagnosis of Gilbert's syndrome: correlation with bilirubin clearance. Gut. 1981;22:663-668.
35. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353-361.
36. Wu BJ, Chen K, Barter PJ, Rye KA. Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation. 2012;125: 150-158.
37. Sarady-Andrews JK, Liu F, Gallo D, Nakao A, Overhaus M, Ollinger R, Choi AM, Otterbein LE. Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol. 2005;289:L1131-L1137.
38. Buch S, Schafmayer C, Volzke H, Seeger M, Miquel JF, Sookoian SC, Egberts JH, Arlt A, Pirola CJ, Lerch MM, John U, Franke A, von Kampen O, Brosch M, Nothnagel M, Kratzer W, Boehm BO, Broring DC, Schreiber S, Krawczak M, Hampe J. Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology. 2010;139:1942-1951.e2.
39. Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res. 2010;16:3832-3842.
40. Owens D, Evans J. Population studies on Gilbert's syndrome. J Med Genet. 1975;12:152-156.
41. Muchova L, Wong RJ, Hsu M, Morioka I, Vitek L, Zelenka J, Schroder H, Stevenson DK. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol. 2007;85:800-810.
42. Hsu M, Muchova L, Morioka I, Wong RJ, Schroder H, Stevenson DK. Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem Biophys Res Commun. 2006;343:738-744.
43. Ali F, Hamdulay SS, Kinderlerer AR, Boyle JJ, Lidington EA, Yamaguchi T, Soares MP, Haskard DO, Randi AM, Mason JC. Statinmediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost. 2007;5:2537-2546.
44. Hu M, Tomlinson B. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia. Atherosclerosis. 2012;223:427-432.
45. de Sauvage Nolting PR, Kusters DM, Hutten BA, Kastelein JJ. Serum bilirubin levels in familial hypercholesterolemia: a new risk marker for cardiovascular disease? J Lipid Res. 2011;52:1755-1759.
46. Schwertner HA, Fischer JR Jr. Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease. Atherosclerosis. 2000;150:381-387.